Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
28 May, 2018 04:48 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Sun Pharmaceutical Industries quarterly earnings up 7% - 25-May-2018 16:12
Tech Mahindra quarterly profit zooms 2.09 times to Rs 12.31 bn - 25-May-2018 16:02
Lupin submits MAA for Etanercept Biosimilar in Europe - 25-May-2018 12:35
HDFC Sec maintains 'Buy' on Granules India - 25-May-2018 11:37
Zydus Cadila gets USFDA nod for Dutasteride, Tamsulosin HCl capsules - 25-May-2018 11:05
Pidilite Industries quarterly earnings surge 57.43% - 25-May-2018 10:34
United Breweries quarterly earnings soar 13.51 times - 25-May-2018 10:23
Larsen & Tubro bags order worth Rs 31.91 bn - 25-May-2018 09:57
MCX strengthens precious metals suite with launch of silver options - 24-May-2018 17:54
Granules India quarterly earnings plummet 55% - 24-May-2018 17:04
GAIL (India) quarterly profit zooms 3.92 times - 24-May-2018 16:58
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer